Medican, founded in October 2017, is a licensed pharmaceutical medical cannabis company headquartered in Helsinge in Denmark. Medican was in December 2017 one of the first Danish companies to obtain an authorization to cultivate medical cannabis following new legislation in Denmark. In July 2020 Medican became the fourth Company to obtain a GACP and EU-GMP Cannabis bulk license, which gives the opportunity to sell and export medical cannabis products. The Company provides patients with the highest quality of medical cannabis as flower and full spectrum oil. The primary markets are Denmark, United Kingdom and Germany. The Company is actively working to secure partnerships and operations in these as well as new markets exploit the development of legalization in Europe.
Medican has developed a very strong strategy with production and cultivation of high quality in-door medical cannabis out of Denmark with distribution to the two largest markets in Europe, Germany and United Kingdom and currently waiting for marketing authorization in further four EU countries. In Germany, Medican has established itself through a 90% owned Medican Pharma GmbH. With Medican Pharma based in Frankfurt Medican has positioned itself in very strong areas in the largest market in Europe
Medican Pharma holds a wholesale license and expected to receive an EU GMP Import license in Q1 2021, which allows the company to handle and produce cannabis products as well as selling consumer ready goods. These licenses are expected in 2020.
The Company was founded and is currently managed by a team with great experience from the international medical cannabis market and with a proven track record of building international growth businesses. Medican has been able to recruit key personnel with a broad experience and previous roles within life science, finance, law, and project management, from both start-ups and already listed companies.
Medican’s mission is to consistently provide European patients with medical-grade cannabis products held to the highest standard of quality.
Medicans vision is to improving quality of life for patients by cultivating consistent, high-quality medical cannabis with compassion and integrity.
Medican’s strategy is cultivation of high-end in-door grown medical cannabis. Distribution and sales are focused on Germany and United Kingdom, however Medican will export to other European markets when legalized. Sales and distribution will primarily take place through Medican’s own associated distribution companies in the specific countries for Medican to secure transparency.
At present, the Company has a Danish indoor cultivation area of 3.000 sq. m and 1.000 sq. meter of EU GMP manufacturing and has already produced several batches in the development phase. The production facility is of state-of-the-art quality to maximize output and limiting costs and is ideally located for export with direct access to the Danish as well as the other key European markets.
Medican Pharma GmbH
Medican Pharma GmbH was established in 2019 and is a Frankfurt-based distributor owned to 90 % by Medican and the remaining 10% owned by the company managing director Morten Brandt. Medican Pharma GmbH was first and foremost established to control distribution and to secure access for patients for information and to buy our products in Germany. Medican Pharma GmbH act as Medican’s preferred distributor of products in Germany and is operated by an experienced pharma- and cannabisteam.
Medican Pharma Ltd
Medican Pharma Ltd was established in 2018., The main focus of the company was to research the UK’s overall market potential for medical cannabis and import from Denmark. The research has been based on three pillars, legislative framework, and development around the cannabis industry, possibilities for import and distribution hub. Legislation has been developing in a positive direction and Medican is currently planning the strategy and organization.